French drugmaker Sanofi has sought to address EU antitrust concerns over its proposed takeover of German peer Boehringer Ingelheim’s consumer health unit by offering concessions.
Sanofi submitted its proposal on July 13, according to a filing on the European Commission website, which did not provide details. It delayed its decision on the deal to Aug. 4 from July 20.
Drugmakers usually offer to sell overlapping assets, either those already on the market or those in the pipeline, to sooth competition worries.
The EU antitrust enforcer is now expected to seek feedback from rivals and third parties before deciding whether to accept the offer, demand more concessions or open a full investigation.
Sanofi’s bid for Boehringer’s consumer health unit with an enterprise value of 6.7 billion euros is part of a $20 billion asset swap in which the German company will acquire its animal health arm.
Full Content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
FTC Withdraws Case Against Microsoft-Activision Merger, Citing Public Interest
May 23, 2025 by
CPI
Charter to Acquire Cox Communications in $35 Billion Deal
May 22, 2025 by
CPI
FTC Targets Media Watchdog Over Alleged Collusion Against Musk’s X
May 22, 2025 by
CPI
FTC Drops Antitrust Case Accusing Pepsi of Squeezing Small Retailers
May 22, 2025 by
CPI
Shein Warns of Higher Costs for French Shoppers Amid EU Fee Proposal
May 22, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Industrial Policy
May 21, 2025 by
CPI
Industrial Strategy and the Role of Competition – Taking a Business Lens
May 21, 2025 by
Marcus Bokkerink
Industrial Policy, Antitrust, and Economic Growth: Some Observations
May 21, 2025 by
David S. Evans
Bolder by Design: Crafting Pro-Competitive Industrial Policies For Complex Challenges
May 21, 2025 by
Antonio Capobianco & Beatriz Marques
Competition-Friendly Industrial Policy
May 21, 2025 by
Philippe Aghion, Mathias Dewatripont & Patrick Legros